This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
Principal Investigator
Virginia Kaklamani
Frances Crawford
(210) 450-5037
crawfordf1@uthscsa.edu
Sonia Creighton
(210) 450-1366
creighton@uthscsa.edu
Myrna Montenegro
(210) 450-5954
montenegro@uthscsa.edu
Courtney Nichols
(210) 450-1794
nicholsc2@uthscsa.edu
Mailbox Ctrc Regulatory Affairs
regaffapp@uthscsa.edu
Regulatory Staff
regaffstaff@uthscsa.edu
Kathleen Rodriguez
(210) 450-1365
rodriguezk3@uthscsa.edu
Benjamin Schleif
(210) 450-1366
schleifb@uthscsa.edu
Morgan Seekatz
(210) 450-1133
seekatz@uthscsa.edu
| Arm | Description | Intervention |
|---|---|---|
Subprotocol B (HER2 activating mutation) | Patients with HER2 activating mutation receive afatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given PO Other names:
Undergo molecular analysis Given PO Other names:
Optional correlative studies Other names:
|
Subprotocol C2 (MET exon 14 deletion/mutation) | Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given PO Other names:
Undergo molecular analysis Optional correlative studies Other names:
|
Subprotocol F (ALK translocation) | Patients with ALK translocation receive crizotinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given PO Other names:
Undergo molecular analysis Optional correlative studies Other names:
|
Subprotocol H (BRAF V600E/R/K/D mutation) | Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given PO Other names:
Undergo molecular analysis Given PO Other names:
Optional correlative studies Other names:
Given PO Other names:
|
Subprotocol J (HER2 amplification >= 7 copy numbers) | Patients with HER2 amplification >= 7 copy numbers receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Given IV Other names:
Given IV Other names:
Optional correlative studies Other names:
Given IV Other names:
|
Subprotocol K2 (FGFR mutation or fusion) | Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Optional correlative studies Other names:
Given PO Other names:
|
Subprotocol M (TSC1 or TSC2 mutation) | Patients with TSC1 or TSC2 mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Optional correlative studies Other names:
Given PO Other names:
|
Subprotocol P (PTEN loss) | Patients with PTEN loss receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Optional correlative studies Other names:
Given PO Other names:
|
Subprotocol A (EGFR activating mutation) | Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given PO Other names:
Undergo molecular analysis Given PO Other names:
Optional correlative studies Other names:
|
Subprotocol C1 (MET amplification) | Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given PO Other names:
Undergo molecular analysis Optional correlative studies Other names:
|
Subprotocol E (EGFR T790M or rare activating mutation) | Patients with EGFR T790M or rare activating mutation receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Given PO Other names:
Optional correlative studies Other names:
|
Subprotocol G (ROS1 translocation or inversion) | Patients with ROS1 translocation or inversion receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given PO Other names:
Undergo molecular analysis Optional correlative studies Other names:
|
Subprotocol I (PIK3CA mutation) | Patients with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Optional correlative studies Other names:
Given PO Other names:
|
Subprotocol K1 (FGFR amplification) | Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Optional correlative studies Other names:
Given PO Other names:
|
Subprotocol L (mTOR mutation) | Patients with mTOR mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Optional correlative studies Other names:
Given PO Other names:
|
Subprotocol N (PTEN mutation or deletion and PTEN expression) | Patients with PTEN mutation or deletion and PTEN expression receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Optional correlative studies Other names:
Given PO Other names:
|
Subprotocol R (BRAF fusion or BRAF non-V600 mutation) | Patients with BRAF fusion or BRAF non-V600 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Given PO Other names:
Optional correlative studies Other names:
|
Subprotocol S2 (GNAQ or GNA11 mutation) | Patients with GNAQ or GNA11 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Given PO Other names:
Optional correlative studies Other names:
|
Subprotocol U (NF2 inactivating mutation) | Patients with NF2 inactivating mutation receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given PO Other names:
Undergo molecular analysis Optional correlative studies Other names:
Given PO |
Subprotocol W (FGFR pathway aberrations) | Patients with FGFR1-3 mutation or translocation receive FGFR Inhibitor AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given PO Other names:
Undergo molecular analysis Optional correlative studies Other names:
|
Subprotocol Y (Akt mutation) | Patients with Akt mutation receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Given PO Other names:
Optional correlative studies Other names:
|
Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC) | Patients with CCND1, 2, or 3 amplification that have tumor Rb expression by IHC receive palbociclib PO QD for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Optional correlative studies Other names:
Given PO Other names:
|
Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC) | Patients with mismatch repair deficiency (loss of MLH1 or MSH2 by IHC) receive nivolumab IV over 30 minutes on days 1 and 15 for 4 cycles and then on day 1 every 28 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Optional correlative studies Other names:
Given IV Other names:
|
Subprotocol Z1F (PIK3CA mutation) | Patients with PIK3CA mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given IV Other names:
Undergo molecular analysis Given IV Other names:
Optional correlative studies Other names:
|
Subprotocol Z1H (PTEN mutation) | Patients with PTEN mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given IV Other names:
Undergo molecular analysis Given IV Other names:
Optional correlative studies Other names:
|
Subprotocol Z1K (AKT mutation) | Patients receive ipatasertib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Optional correlative studies Other names:
Given PO Other names:
|
Subprotocol Z1M (LAG-3 expression >= 1%) | Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1.Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Given IV Other names:
Optional correlative studies Other names:
Given IV Other names:
|
Subprotocol Q (HER2 amplification) | Patients with HER2 amplification receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Given IV Other names:
Optional correlative studies Other names:
Given IV Other names:
|
Subprotocol S1 (NF1 mutation) | Patients with NF1 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Given PO Other names:
Optional correlative studies Other names:
|
Subprotocol T (SMO or PTCH1 mutation) | Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Given PO Other names:
Optional correlative studies Other names:
|
Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation) | Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib malate PO QD for 4 weeks. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Given PO Other names:
Optional correlative studies Other names:
|
Subprotocol X (DDR2 S768R, I638F, or L239R mutation) | Patients with DDR2 S768R, I638F, or L239R mutation receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given PO Other names:
Undergo molecular analysis Optional correlative studies Other names:
|
Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61) | Patients with NRAS mutation in codon 12, 13, or 61 receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given PO Other names:
Undergo molecular analysis Optional correlative studies Other names:
|
Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein) | Patients with CDK4 or CDK6 amplification and tumor Rb protein receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Optional correlative studies Other names:
Given PO Other names:
|
Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion) | Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Given PO Other names:
Optional correlative studies Other names:
Given PO Other names:
|
Subprotocol Z1G (PTEN loss) | Patients with PTEN loss receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Given IV Other names:
Undergo molecular analysis Given IV Other names:
Optional correlative studies Other names:
|
Subprotocol Z1I (BRCA1 or BRCA2 gene mutation) | Patients with BRCA1 or BRCA2 gene mutation receive adavosertib PO QD for 5 days for 2 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Given PO Other names:
Optional correlative studies Other names:
|
Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation) | Patients with a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration receive ulixertinib (BVD-523FB) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Undergo molecular analysis Optional correlative studies Other names:
Give PO Other names:
|